Psychiatrists Dismiss Patient Evidence Against ECT as “Anecdotal” to Protect Profits
In 2015, the U.S. Food and Drug Administration issued its “Neurological Devices; Reclassification of Electroconvulsive Therapy Devices Intended for Use in Treating,” recommending that the ECT device be rated Class II (less risk classification than its current Class III) for: Severe major depressive episode (MDE) associated with major depressive disorder (MDD) or bipolar disorder (BPD) … Read more